Deals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates
AbbVieBrise Pharmaceuticals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

Brise Pharmaceuticals Co. Ltd., a portfolio company of Sherpa Healthcare Partners, announced an update on its exclusive license agreement with AbbVie (NYSE: ABBV), originally entered into in 2024. Under the…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials
CircurnauBriGene Biosciences

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option
Dren BioNASDAQ: SNY

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis
Adaptive BiotechnologiesAI

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio
Arthrosi TherapeuticsHKG: 1873

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Show More